Cellular response to chemotherapy and radiation in cervical cancer
- PMID: 15902120
- DOI: 10.1016/j.ajog.2004.12.045
Cellular response to chemotherapy and radiation in cervical cancer
Abstract
Effect of irradiation alone and irradiation after 5-fluorouracil (5-FU), paclitaxel, or cisplatin (CDDP) was investigated in human cervical cell lines (CaSki, ME180, SiHa, and C33A). High-risk human papillomavirus (HPV) (+) CaSki and SiHa cells were the most resistant to CDDP, 5-FU, and radiation treatments. Radiation and CDDP and 5-FU resulted in decreased survival of HPV 16 and 18 (+) cells, whereas addition of paclitaxel to radiation treatments decreased killing. Enhanced killing of ME180 cells containing HPV39 sequences was demonstrated with chemoradiotherapy with all agents. HPV(-) C33A was more sensitive to radiation than the other cell lines, and the addition of chemotherapeutic agents did not result in significant change in cytotoxicity. Expression of survivin was inversely proportional to cell sensitivity to CDDP, 5-FU, and radiation. Constitutive AKT levels are the lowest in cell lines that are the most resistant to CDDP, 5-FU, and radiation. These data provide correlation of response to combined therapeutic modalities with HPV status of cervical cancer and expression of survivin and AKT.
Similar articles
-
Evidence of an association between human papillomavirus and impaired chemotherapy-induced apoptosis in cervical cancer cells.Gynecol Oncol. 2002 Apr;85(1):59-66. doi: 10.1006/gyno.2002.6604. Gynecol Oncol. 2002. PMID: 11925121
-
Potentiation of the radiation effect with genistein in cervical cancer cells.Gynecol Oncol. 2005 Oct;99(1):199-205. doi: 10.1016/j.ygyno.2005.07.002. Gynecol Oncol. 2005. PMID: 16083949
-
Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.Biomed Pharmacother. 2007 Jul;61(6):347-55. doi: 10.1016/j.biopha.2007.02.007. Epub 2007 Mar 9. Biomed Pharmacother. 2007. PMID: 17399942
-
Breaking the DNA damage response to improve cervical cancer treatment.Cancer Treat Rev. 2016 Jan;42:30-40. doi: 10.1016/j.ctrv.2015.11.008. Epub 2015 Nov 24. Cancer Treat Rev. 2016. PMID: 26643553 Review.
-
Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance.Lancet Oncol. 2005 Aug;6(8):589-98. doi: 10.1016/S1470-2045(05)70281-3. Lancet Oncol. 2005. PMID: 16054570 Review.
Cited by
-
HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4.Tumour Biol. 2015 Dec;36(12):9987-94. doi: 10.1007/s13277-015-3782-7. Epub 2015 Jul 19. Tumour Biol. 2015. PMID: 26188903
-
Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy.Technol Cancer Res Treat. 2017 Dec;16(6):705-716. doi: 10.1177/1533034617737011. Epub 2017 Oct 31. Technol Cancer Res Treat. 2017. PMID: 29332468 Free PMC article. Review.
-
Knock down of p53 or its ubiquitin ligase E6AP does not affect the sensitivity of human papillomavirus-positive cervical cancer cells to cisplatin.Am J Cancer Res. 2012;2(3):309-21. Epub 2012 Apr 22. Am J Cancer Res. 2012. PMID: 22679561 Free PMC article.
-
Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents.Biomed Res Int. 2014;2014:574659. doi: 10.1155/2014/574659. Epub 2014 Nov 16. Biomed Res Int. 2014. PMID: 25478571 Free PMC article.
-
Human papillomavirus oncoproteins differentially modulate epithelial-mesenchymal transition in 5-FU-resistant cervical cancer cells.Tumour Biol. 2016 Oct;37(10):13137-13154. doi: 10.1007/s13277-016-5143-6. Epub 2016 Jul 24. Tumour Biol. 2016. PMID: 27449048
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous